Revisiting RAAS blockade in CKD with newer potassium-binding drugs
Author:
Funder
U.S. Department of Veterans Affairs
National Institutes of Health
Publisher
Elsevier BV
Subject
Nephrology
Reference57 articles.
1. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease;Am J Kidney Dis,2004
2. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC);Mancia;J Hypertens,2013
3. Aggressive blood pressure reduction and renin-angiotensin system blockade in chronic kidney disease: time for re-evaluation?;Sarafidis;Kidney Int,2014
4. Summary of KDIGO guideline. What do we really know about management of blood pressure in patients with chronic kidney disease?;Wheeler;Kidney Int,2013
5. Antihypertensive therapy in the presence of proteinuria;Sarafidis;Am J Kidney Dis,2007
Cited by 63 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Sanqi oral solution ameliorates renal fibrosis by suppressing fibroblast activation via HIF-1α/PKM2/glycolysis pathway in chronic kidney disease;Journal of Ethnopharmacology;2024-12
2. Clinical Outcomes of Renin-Angiotensin-Aldosterone Blockade in Patients With Advanced Chronic Kidney Disease: A Systematic Review and Meta-analysis;Canadian Journal of Cardiology;2024-09
3. The significance of finerenone as a novel therapeutic option in diabetic kidney disease: a scoping review with emphasis on cardiorenal outcomes of the finerenone phase 3 trials;Frontiers in Medicine;2024-06-14
4. Angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic kidney disease;Cochrane Database of Systematic Reviews;2024-04-29
5. Protocol for systematic review and meta-analysis for randomized clinical trials on patiromer efficacy and safety in subjects with heart failure;PHARM PRACT-GRANADA;2024
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3